| Record Information |
| Version |
3.5 |
| Creation Date |
2005-11-16 08:48:42 -0700 |
| Update Date |
2013-02-08 17:08:08 -0700 |
| HMDB ID |
HMDB00234 |
| Secondary Accession Numbers |
None |
| Metabolite Identification |
| Common Name |
Testosterone |
| Description |
Testosterone is the most important androgen in potency and quantity. Testosterone is synthesized and released by the Leydig cells that lie between the tubules and comprise less than 5% of the total testicular volume. testosterone diffuses into the seminiferous tubules where it is essential for maintaining spermatogenesis. Some binds to an androgen-binding protein (ABP) that is produced by the Sertoli cells and is homologous to the sex-hormone binding globulin that transports testosterone in the general circulation. The ABP carries testosterone in the testicular fluid where it maintains the activity of the accessory sex glands and may also help to retain testosterone within the tubule and bind excess free hormone. Some testosterone is converted to estradiol by Sertoli cell-derived aromatase enzyme. Leydig cell steroidogenesis is controlled primarily by luteinizing hormone with negative feedback of testosterone on the hypothalamic-pituitary axis. The requirement of spermatogenesis for high local concentrations of testosterone means that loss of androgen production is likely to be accompanied by loss of spermatogenesis. Indeed, if testicular androgen production is inhibited by the administration of exogenous androgens then spermatogenesis ceases. This is the basis of using exogenous testosterone as a male contraceptive. testosterone is converted to dihydrotestosterone by 5a-reductase type 2 (EC 1.3.1.22, SRD5A2), the androgen with the highest affinity for the androgen receptor. SRD5A2 deficiency illustrates the importance of dihydrotestosterone for external virilization, as individuals with this condition have normal male internal structures but their external genitalia are of female appearance. There is now clear evidence that the human fetal testis and also the fetal adrenal gland is capable of testosterone biosynthesis during the first trimester. Regardless of the source of androgen production, the target tissue responds by male sexual differentiation of the external genitalia by the end of the first trimester. It is clear that testicular damage may result in loss of testosterone production or the loss of spermatogenesis or both. Loss of androgen production results in hypogonadism, the symptoms of which reflect the functions of testosterone. Male hypogonadism is defined as failure of the testes to produce normal amounts of testosterone, combined with signs and symptoms of androgen deficiency. Systemic testosterone levels fall by about 1% each year in men. Therefore, with increasing longevity and the aging of the population, the number of older men with testosterone deficiency will increase substantially over the next several decades. Serum testosterone levels decrease progressively in aging men, but the rate and magnitude of decrease vary considerably. Approximately 1% of healthy young men have total serum testosterone levels below normal; in contrast, approximately 20% of healthy men over age 60 years have serum testosterone levels below normal. (PMID: 17904450 , 17875487 ). |
| Structure |
Download:
MOL |
SDF |
SMILES |
InChI
Display:
2D Structure |
3D Structure
|
| Synonyms |
- (+)-testosterone
- (+-)-8-iso-testosterone
- (+-)-retrotestosterone
- (+-)-testosterone
- (17b)-17-hydroxy-androst-4-en-3-one
- 13-Iso-testosterone
- 17-Hydroxy-10,13-dimethyl-1,2,6,7,8,9,10,11,12,13,14,15,16,17-tetradecahydro-cyclopenta[a]phenanthren-3-one
- 17-Hydroxy-androst-4-en-3-one
- 17-Hydroxy-D4-androsten-3-one
- 17a-Hydroxy-(13a)-androst-4-en-3-one
- 17a-Hydroxy-13a-androst-4-en-3-one
- 17a-Hydroxy-14b-androst-4-en-3-one
- 17a-Hydroxy-androst-4-en-3-one
- 17b-Hydroxy-(10a)-androst-4-en-3-one
- 17b-Hydroxy-(13a)-androst-4-en-3-one
- 17b-Hydroxy-(8a)-androst-4-en-3-one
- 17b-Hydroxy-(8a,10a)-androst-4-en-3-one
- 17b-Hydroxy-(9b)-androst-4-en-3-one
- 17b-Hydroxy-(9b,10a)-androst-4-en-3-one
- 17b-Hydroxy-13a-androst-4-en-3-one
- 17b-Hydroxy-8a-androst-4-en-3-one
- 17b-Hydroxy-androst-4-en-3-on
- 17b-Hydroxy-androst-4-en-3-one
- 17b-Hydroxy-D4-androsten-3-one
- 17b-Hydroxyandrost-4-en-3-one
- 17b-Hydroxyandrost-4-ene-3-one
- 17b-Testosterone
- 4-Androsten-3-one-17b-ol
- 8-Iso-testosterone
- 9b,10a-Testosterone
- 9b-Testosterone
- Androderm
- AndroGel
- Androlin
- Andronaq
- Andropatch
- Androst-4-en-17b-ol-3-one
- Androst-4-ene-17b-ol-3-one
- Andrusol
- Cristerona T
- D4-Androsten-17b-ol-3-one
- Epitestosteron
- Geno-cristaux Gremy
- Homosteron
- Homosterone
- Lumitestosteron
- Mertestate
- Neotestis
- Oreton
- Orquisteron
- Perandren
- Percutacrine androgenique
- Primotest
- Primoteston
- Rac-17b-hydroxy-(13a)androst-4-en-3-one
- Rac-17b-hydroxy-(8a)-androst-4-en-3-one
- Rac-17b-hydroxy-(9b,10a)androst-4-en-3-one
- Rac-17b-hydroxy-androst-4-en-3-one
- Relibra
- Retrotestosterone
- Sustanon
- Sustanone
- Sustason 250
- Synandrol F
- Teslen
- Testandrone
- Testiculosterone
- Testim
- Testobase
- Testoderm
- Testogel
- Testolent
- Testolin
- Testopropon
- Testosteroid
- Testosteron
- Testoviron Schering
- Testoviron T
- Testro AQ
- Testrone
- Testryl
- Tostrelle
- Tostrex
- Viatrel
- Virormone
- Virosterone
|
| Chemical Formula |
C19H28O2 |
| Average Molecular Weight |
288.4244 |
| Monoisotopic Molecular Weight |
288.20893014 |
| IUPAC Name |
(1S,2R,10R,11S,14S,15S)-14-hydroxy-2,15-dimethyltetracyclo[8.7.0.0^{2,7}.0^{11,15}]heptadec-6-en-5-one |
| Traditional IUPAC Name |
testosterone |
| CAS Registry Number |
58-22-0 |
| SMILES |
[H][C@@]12CC[C@H](O)[C@@]1(C)CC[C@@]1([H])[C@@]2([H])CCC2=CC(=O)CC[C@]12C |
| InChI Identifier |
InChI=1S/C19H28O2/c1-18-9-7-13(20)11-12(18)3-4-14-15-5-6-17(21)19(15,2)10-8-16(14)18/h11,14-17,21H,3-10H2,1-2H3/t14-,15-,16-,17-,18-,19-/m0/s1 |
| InChI Key |
MUMGGOZAMZWBJJ-DYKIIFRCSA-N |
| Chemical Taxonomy |
| Kingdom |
Organic Compounds |
| Super Class |
Lipids |
| Class |
Steroids and Steroid Derivatives |
| Sub Class |
Androgens and Derivatives |
| Other Descriptors |
- Aliphatic Homopolycyclic Compounds
- Hydroxysteroids
- Ketosteroids
- a hormone(Cyc)
|
| Substituents |
- Cyclic Alcohol
- Cyclohexane
- Cyclohexene
- Decaline
- Ketone
- Secondary Alcohol
- Sesquiterpene Backbone
|
| Direct Parent |
Androgens and Derivatives |
| Ontology |
| Status |
Detected and Quantified |
| Origin |
|
| Biofunction |
- Cell signaling
- Fuel and energy storage
- Fuel or energy source
- Hormones, Membrane component
- Membrane integrity/stability
|
| Application |
- Nutrients
- Stabilizers
- Surfactants and Emulsifiers
|
| Cellular locations |
- Cytoplasm
- Extracellular
- Membrane (predicted from logP)
- Endoplasmic reticulum
|
| Physical Properties |
| State |
Solid |
| Experimental Properties |
| Property |
Value |
Reference |
| Melting Point |
155 °C |
Not Available |
| Boiling Point |
Not Available |
Not Available |
| Water Solubility |
0.0234 mg/mL |
Not Available |
| LogP |
3.32 |
HANSCH,C ET AL. (1995) |
|
| Predicted Properties |
|
| Spectra |
|
|
| Biological Properties |
| Cellular Locations |
- Cytoplasm
- Extracellular
- Membrane (predicted from logP)
- Endoplasmic reticulum
|
| Biofluid Locations |
- Blood
- Cerebrospinal Fluid (CSF)
- Saliva
- Urine
|
| Tissue Location |
- Muscle
- Testes
- Brain
- Gonads
- Sperm
- Hypothalamus
|
| Pathways |
|
| Normal Concentrations |
|
| Blood |
Detected and Quantified |
|
0.00125 +/- 0.00042 uM |
Adult (>18 years old) |
Female |
Normal |
Not Available |
| Blood |
Detected and Quantified |
|
0.013 (0.0083-0.0286) uM |
Adult (>18 years old) |
Male |
Normal |
Not Available |
| Blood |
Detected and Quantified |
|
0.0094 +/- 0.0014 uM |
Adult (>18 years old) |
Male |
Normal |
Not Available |
| Cerebrospinal Fluid (CSF) |
Detected and Quantified |
|
0.00101 (0.00002-0.002) uM |
Adult (>18 years old) |
Not Specified |
Normal |
Not Available |
| Cerebrospinal Fluid (CSF) |
Detected and Quantified |
|
0.00065 +/- 0.00012 uM |
Adult (>18 years old) |
Male |
Normal |
Not Available |
| Saliva |
Detected and Quantified |
|
0.00120 (0.00108-0.00133) uM |
Adult (>18 years old) |
Male |
Normal |
Not Available |
| Saliva |
Detected and Quantified |
|
0.000677 (0.000590-0.000764) uM |
Adult (>18 years old) |
Female |
Normal |
Not Available |
| Urine |
Detected and Quantified |
|
0.000121 +/- 0.00002149 umol/mmol creatinine |
Adult (>18 years old) |
Both |
Normal |
Not Available |
| Urine |
Detected and Quantified |
|
1.07 +/- 0.19 umol/mmol creatinine |
Adult (>18 years old) |
Both |
Normal |
Not Available |
|
| Abnormal Concentrations |
|
| Blood |
Detected and Quantified |
|
9.31 (3.31-19.95) uM |
Adult (>18 years old) |
Male |
Cadmium exposure |
Not Available |
| Blood |
Detected and Quantified |
|
0.010 +/- 0.013 uM |
Adolescent (13-18 years old) |
Male |
Hypogonadism |
Not Available |
| Cerebrospinal Fluid (CSF) |
Detected and Quantified |
|
3.400e-05 +/- 1.665e-05 uM |
Adult (>18 years old) |
Not Specified |
Leuprolide acetate-induce hypogonadism |
Not Available |
| Cerebrospinal Fluid (CSF) |
Detected and Quantified |
|
0.000497 +/- 0.000222 uM |
Adult (>18 years old) |
Not Specified |
Leuprolide acetate-induced hypogonadism with testosterone replacment |
Not Available |
|
| Associated Disorders and Diseases |
| Disease References |
| Hypogonadism |
- http://en.wikipedia.org/wiki/Testosterone
|
| Cadmium exposure |
- Zeng X, Lin T, Zhou Y, Kong Q: Alterations of serum hormone levels in male workers occupationally exposed to cadmium. J Toxicol Environ Health A. 2002 Apr 12;65(7):513-21.
Pubmed: 11939709
|
|
| Associated OMIM IDs |
None |
| External Links |
| DrugBank ID |
DB00624  |
| Phenol Explorer Compound ID |
Not Available |
| Phenol Explorer Metabolite ID |
Not Available |
| FoodDB ID |
FDB011544 |
| KNApSAcK ID |
C00003675  |
| Chemspider ID |
5791  |
| KEGG Compound ID |
C00535  |
| BioCyc ID |
Not Available |
| BiGG ID |
35280  |
| Wikipedia Link |
Testosterone  |
| NuGOwiki Link |
HMDB00234  |
| Metagene Link |
HMDB00234  |
| METLIN ID |
390  |
| PubChem Compound |
6013  |
| PDB ID |
TES  |
| ChEBI ID |
17347  |
| References |
| Synthesis Reference |
Ercoli, Alberto; De Ruggieri, Pietro. An improved method of preparing testosterone, dihydrotestosterone, and some of their esters. Journal of the American Chemical Society (1953), 75 650-3. |
| Material Safety Data Sheet (MSDS) |
Download (PDF)
|
| General References |
- Handelsman DJ: Clinical review: The rationale for banning human chorionic gonadotropin and estrogen blockers in sport. J Clin Endocrinol Metab. 2006 May;91(5):1646-53. Epub 2006 Feb 14.
Pubmed: 16478815
- Duschek EJ, Gooren LJ, Netelenbos C: Comparison of effects of the rise in serum testosterone by raloxifene and oral testosterone on serum insulin-like growth factor-1 and insulin-like growth factor binding protein-3. Maturitas. 2005 Jul 16;51(3):286-93.
Pubmed: 15978972
- Schaap LA, Pluijm SM, Smit JH, van Schoor NM, Visser M, Gooren LJ, Lips P: The association of sex hormone levels with poor mobility, low muscle strength and incidence of falls among older men and women. Clin Endocrinol (Oxf). 2005 Aug;63(2):152-60.
Pubmed: 16060908
- Kim YS, Zhang H, Kim HY: Profiling neurosteroids in cerebrospinal fluids and plasma by gas chromatography/electron capture negative chemical ionization mass spectrometry. Anal Biochem. 2000 Jan 15;277(2):187-95.
Pubmed: 10625505
- Huang I, Jones J, Khorram O: Human seminal plasma nitric oxide: correlation with sperm morphology and testosterone. Med Sci Monit. 2006 Mar;12(3):CR103-6. Epub 2006 Feb 23.
Pubmed: 16501419
- Hussein A, Ozgok Y, Ross L, Niederberger C: Clomiphene administration for cases of nonobstructive azoospermia: a multicenter study. J Androl. 2005 Nov-Dec;26(6):787-91; discussion 792-3.
Pubmed: 16291975
- Ahtiainen JP, Pakarinen A, Alen M, Kraemer WJ, Hakkinen K: Short vs. long rest period between the sets in hypertrophic resistance training: influence on muscle strength, size, and hormonal adaptations in trained men. J Strength Cond Res. 2005 Aug;19(3):572-82.
Pubmed: 16095405
- Landman AD, Sanford LM, Howland BE, Dawes C, Pritchard ET: Testosterone in human saliva. Experientia. 1976;32(7):940-1.
Pubmed: 954994
- Knickmeyer RC, Wheelwright S, Taylor K, Raggatt P, Hackett G, Baron-Cohen S: Gender-typed play and amniotic testosterone. Dev Psychol. 2005 May;41(3):517-28.
Pubmed: 15910159
- Fejes I, Koloszar S, Szollosi J, Zavaczki Z, Pal A: Is semen quality affected by male body fat distribution? Andrologia. 2005 Oct;37(5):155-9.
Pubmed: 16266392
- Jarow JP, Zirkin BR: The androgen microenvironment of the human testis and hormonal control of spermatogenesis. Ann N Y Acad Sci. 2005 Dec;1061:208-20.
Pubmed: 16467270
- Rovensky J, Radikova Z, Imrich R, Greguska O, Vigas M, Macho L: Gonadal and adrenal steroid hormones in plasma and synovial fluid of patients with rheumatoid arthritis. Endocr Regul. 2004 Dec;38(4):143-9.
Pubmed: 15841793
- Klimek M, Pabian W, Tomaszewska B, Kolodziejczyk J: Levels of plasma ACTH in men from infertile couples. Neuro Endocrinol Lett. 2005 Aug;26(4):347-50.
Pubmed: 16136011
- Cutolo M, Sulli A, Capellino S, Villaggio B, Montagna P, Pizzorni C, Paolino S, Seriolo B, Felli L, Straub RH: Anti-TNF and sex hormones. Ann N Y Acad Sci. 2006 Jun;1069:391-400.
Pubmed: 16855166
- Schwarz S, Pohl P: Steroid hormones and steroid hormone binding globulins in cerebrospinal fluid studied in individuals with intact and with disturbed blood-cerebrospinal fluid barrier. Neuroendocrinology. 1992 Feb;55(2):174-82.
Pubmed: 1620285
- Shores MM, Matsumoto AM, Sloan KL, Kivlahan DR: Low serum testosterone and mortality in male veterans. Arch Intern Med. 2006 Aug 14-28;166(15):1660-5.
Pubmed: 16908801
- Bhasin S, Cunningham GR, Hayes FJ, Matsumoto AM, Snyder PJ, Swerdloff RS, Montori VM: Testosterone therapy in adult men with androgen deficiency syndromes: an endocrine society clinical practice guideline. J Clin Endocrinol Metab. 2006 Jun;91(6):1995-2010. Epub 2006 May 23.
Pubmed: 16720669
- Archer JS, Love-Geffen TE, Herbst-Damm KL, Swinney DA, Chang JR: Effect of estradiol versus estradiol and testosterone on brain-activation patterns in postmenopausal women. Menopause. 2006 May-Jun;13(3):528-37.
Pubmed: 16735951
- Jarow JP, Wright WW, Brown TR, Yan X, Zirkin BR: Bioactivity of androgens within the testes and serum of normal men. J Androl. 2005 May-Jun;26(3):343-8.
Pubmed: 15867001
- Bridger T, MacDonald S, Baltzer F, Rodd C: Randomized placebo-controlled trial of metformin for adolescents with polycystic ovary syndrome. Arch Pediatr Adolesc Med. 2006 Mar;160(3):241-6.
Pubmed: 16520442
|
| Enzymes |
|
|
| Name: |
Estrogen sulfotransferase
|
| Reactions: |
- 3'-phosphoadenylyl sulfate + estrone = adenosine 3',5'-bisphosphate + estrone 3-sulfate [RN:R02350]
|
| Gene Name: |
SULT1E1 |
| Uniprot ID: |
P49888  |
| Protein Sequence: |
FASTA |
| Gene Sequence: |
FASTA |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Name: |
3-oxo-5-beta-steroid 4-dehydrogenase
|
| Reactions: |
- (1) 5beta-cholestan-3-one + NADP+ = cholest-4-en-3-one + NADPH + H+ [RN:R02609]
- (2) 17,21-dihydroxy-5beta-pregnane-3,11,20-trione + NADP+ = cortisone + NADPH + H+ [RN:R02893]
|
| Gene Name: |
AKR1D1 |
| Uniprot ID: |
P51857  |
| Protein Sequence: |
FASTA |
| Gene Sequence: |
FASTA |
|
|
|
|
|
|
|
|
|
|
|
| Name: |
Cytochrome P450 3A4
|
| Reactions: |
- (1) taurochenodeoxycholate + NADPH + H+ + O2 = taurohyocholate + NADP+ + H2O [RN:R07205]
- (2) lithocholate + NADPH + H+ + O2 = hyodeoxycholate + NADP+ + H2O [RN:R07206]
|
| Gene Name: |
CYP3A4 |
| Uniprot ID: |
P08684  |
| Protein Sequence: |
FASTA |
| Gene Sequence: |
FASTA |
|
| Name: |
Cytochrome P450 2C9
|
| Reactions: |
- (R)-limonene + NADPH + H+ + O2 = (+)-trans-carveol + NADP+ + H2O [RN:R06119]
|
| Gene Name: |
CYP2C9 |
| Uniprot ID: |
P11712  |
| Protein Sequence: |
FASTA |
| Gene Sequence: |
FASTA |
|
| Name: |
Cytochrome P450 2C19
|
| Reactions: |
- (R)-limonene + NADPH + H+ + O2 = (+)-trans-carveol + NADP+ + H2O [RN:R06119]
|
| Gene Name: |
CYP2C19 |
| Uniprot ID: |
P33261  |
| Protein Sequence: |
FASTA |
| Gene Sequence: |
FASTA |
|
|
|
| Name: |
Cytochrome P450 3A43
|
| Reactions: |
- RH + reduced flavoprotein + O2 = ROH + oxidized flavoprotein + H2O [RN:R04122]
|
| Gene Name: |
CYP3A43 |
| Uniprot ID: |
Q9HB55  |
| Protein Sequence: |
FASTA |
| Gene Sequence: |
FASTA |
|
| Name: |
Cytochrome P450 1B1
|
| Reactions: |
- RH + reduced flavoprotein + O2 = ROH + oxidized flavoprotein + H2O [RN:R04122]
|
| Gene Name: |
CYP1B1 |
| Uniprot ID: |
Q16678  |
| Protein Sequence: |
FASTA |
| Gene Sequence: |
FASTA |
|
| Name: |
Cytochrome P450 2C18
|
| Reactions: |
- RH + reduced flavoprotein + O2 = ROH + oxidized flavoprotein + H2O [RN:R04122]
|
| Gene Name: |
CYP2C18 |
| Uniprot ID: |
P33260  |
| Protein Sequence: |
FASTA |
| Gene Sequence: |
FASTA |
|
| Name: |
Cytochrome P450 2F1
|
| Reactions: |
- RH + reduced flavoprotein + O2 = ROH + oxidized flavoprotein + H2O [RN:R04122]
|
| Gene Name: |
CYP2F1 |
| Uniprot ID: |
P24903  |
| Protein Sequence: |
FASTA |
| Gene Sequence: |
FASTA |
|
| Name: |
Cytochrome P450 4X1
|
| Reactions: |
- RH + reduced flavoprotein + O2 = ROH + oxidized flavoprotein + H2O [RN:R04122]
|
| Gene Name: |
CYP4X1 |
| Uniprot ID: |
Q8N118  |
| Protein Sequence: |
FASTA |
| Gene Sequence: |
FASTA |
|
| Name: |
Cytochrome P450 2B6
|
| Reactions: |
- RH + reduced flavoprotein + O2 = ROH + oxidized flavoprotein + H2O [RN:R04122]
|
| Gene Name: |
CYP2B6 |
| Uniprot ID: |
P20813  |
| Protein Sequence: |
FASTA |
| Gene Sequence: |
FASTA |
|
| Name: |
Cytochrome P450 3A5
|
| Reactions: |
- RH + reduced flavoprotein + O2 = ROH + oxidized flavoprotein + H2O [RN:R04122]
|
| Gene Name: |
CYP3A5 |
| Uniprot ID: |
P20815  |
| Protein Sequence: |
FASTA |
| Gene Sequence: |
FASTA |
|
| Name: |
Cytochrome P450 1A1
|
| Reactions: |
- RH + reduced flavoprotein + O2 = ROH + oxidized flavoprotein + H2O [RN:R04122]
|
| Gene Name: |
CYP1A1 |
| Uniprot ID: |
P04798  |
| Protein Sequence: |
FASTA |
| Gene Sequence: |
FASTA |
|
| Name: |
Cytochrome P450 2A13
|
| Reactions: |
- RH + reduced flavoprotein + O2 = ROH + oxidized flavoprotein + H2O [RN:R04122]
|
| Gene Name: |
CYP2A13 |
| Uniprot ID: |
Q16696  |
| Protein Sequence: |
FASTA |
| Gene Sequence: |
FASTA |
|
| Name: |
Cytochrome P450 3A7
|
| Reactions: |
- RH + reduced flavoprotein + O2 = ROH + oxidized flavoprotein + H2O [RN:R04122]
|
| Gene Name: |
CYP3A7 |
| Uniprot ID: |
P24462  |
| Protein Sequence: |
FASTA |
| Gene Sequence: |
FASTA |
|
| Name: |
Cytochrome P450 4B1
|
| Reactions: |
- RH + reduced flavoprotein + O2 = ROH + oxidized flavoprotein + H2O [RN:R04122]
|
| Gene Name: |
CYP4B1 |
| Uniprot ID: |
P13584  |
| Protein Sequence: |
FASTA |
| Gene Sequence: |
FASTA |
|
| Name: |
Cytochrome P450 4Z1
|
| Reactions: |
- RH + reduced flavoprotein + O2 = ROH + oxidized flavoprotein + H2O [RN:R04122]
|
| Gene Name: |
CYP4Z1 |
| Uniprot ID: |
Q86W10  |
| Protein Sequence: |
FASTA |
| Gene Sequence: |
FASTA |
|
| Name: |
Cytochrome P450 1A2
|
| Reactions: |
- RH + reduced flavoprotein + O2 = ROH + oxidized flavoprotein + H2O [RN:R04122]
|
| Gene Name: |
CYP1A2 |
| Uniprot ID: |
P05177  |
| Protein Sequence: |
FASTA |
| Gene Sequence: |
FASTA |
|
| Name: |
Cytochrome P450 19A1
|
| Reactions: |
- RH + reduced flavoprotein + O2 = ROH + oxidized flavoprotein + H2O [RN:R04122]
|
| Gene Name: |
CYP19A1 |
| Uniprot ID: |
P11511  |
| Protein Sequence: |
FASTA |
| Gene Sequence: |
FASTA |
|
| Name: |
Cytochrome P450 2C8
|
| Reactions: |
- RH + reduced flavoprotein + O2 = ROH + oxidized flavoprotein + H2O [RN:R04122]
|
| Gene Name: |
CYP2C8 |
| Uniprot ID: |
P10632  |
| Protein Sequence: |
FASTA |
| Gene Sequence: |
FASTA |
|
| Name: |
Cytochrome P450 2S1
|
| Reactions: |
- RH + reduced flavoprotein + O2 = ROH + oxidized flavoprotein + H2O [RN:R04122]
|
| Gene Name: |
CYP2S1 |
| Uniprot ID: |
Q96SQ9  |
| Protein Sequence: |
FASTA |
| Gene Sequence: |
FASTA |
|
| Name: |
Cytochrome P450 2J2
|
| Reactions: |
- RH + reduced flavoprotein + O2 = ROH + oxidized flavoprotein + H2O [RN:R04122]
|
| Gene Name: |
CYP2J2 |
| Uniprot ID: |
P51589  |
| Protein Sequence: |
FASTA |
| Gene Sequence: |
FASTA |
|
| Name: |
Cytochrome P450 2A7
|
| Reactions: |
- RH + reduced flavoprotein + O2 = ROH + oxidized flavoprotein + H2O [RN:R04122]
|
| Gene Name: |
CYP2A7 |
| Uniprot ID: |
P20853  |
| Protein Sequence: |
FASTA |
| Gene Sequence: |
FASTA |
|
| Name: |
Cytochrome P450 2A6
|
| Reactions: |
- RH + reduced flavoprotein + O2 = ROH + oxidized flavoprotein + H2O [RN:R04122]
|
| Gene Name: |
CYP2A6 |
| Uniprot ID: |
P11509  |
| Protein Sequence: |
FASTA |
| Gene Sequence: |
FASTA |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|